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Preclinical investigation to compare different
gadolinium-based contrast agents regarding
their propensity to release gadolinium in vivo
and to trigger nephrogenic systemic
fibrosis-like lesions
Abstract Recent reports suggest that
nephrogenic systemic fibrosis (NSF)
is associated with the administration
of gadolinium (Gd)-based contrast
agents (GBCAs) and in particular with
the stability of the Gd-complex. The
aim of this investigation was to
compare GBCAs and their potential to
trigger NSF. Forty-two healthy male
rats received repeated intravenous
injections of six different GBCAs at
high doses to simulate the exposure
seen in patients with severe renal
dysfunction. Histopathological and
immunohistochemical analysis of
the skin was performed, and the
concentrations of Gd, zinc and copper
were measured in several tissues by
inductive coupled plasma atomic
emission spectroscopy. Macroscopic
and histological skin changes similar
to those seen in NSF patients were
only observed in rats receiving
Omniscan. In addition, very high
concentrations of Gd were observed in
the animals treated with Omniscan,
and, to a lesser extent, in animals
treated with OptiMARK. Significantly
lower levels of Gd were found after
the treatment with ionic linear agents
and even less after the treatment with
macrocyclic agents. The data in this
investigation strongly suggest that the
stability of the Gd-complex is a key
factor for the development of NSF-
like symptoms in this experimental
setting.
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Introduction
Nephrogenic systemic fibrosis (NSF) is a rare, but serious
disorder that is characterized by fibrosis of the skin and of
connective tissues throughout the body [1].
Although first described in the medical literature in
2000, the first reported case of NSF dates back to 19971
[2]. Since then, the number of reports of NSF has increased
with more than 250 reports of NSF filed with regulatory
authorities worldwide as of August 2007 [3]. Although the
exact etiology of NSF is currently unknown, it is most
likely multifactorial and, to date has only been reported in
patients with severe renal insufficiency [4], many of whom
were on hemodialysis or peritoneal dialysis [5]. Recent
case reports and data from animal experiments suggest an
association between NSF and exposure to gadolinium
(Gd)-based contrast agents (GBCAs) [6–8], although NSF
without prior Gd exposure has also been reported [9, 10].
One theory suggests that the incidence of NSF is
correlated to the stability of the various GBCAs [11]. The
majority of cases reported to date relate to the use of one
1However, the actual term ‘Nephrogenic Systemic Fibrosis’ was
introduced much later.
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agent in particular, gadodiamide (Omniscan®, Gd-DTPA-
BMA), however, there are also reports with other agents
such as gadoversetamide (OptiMark®, Gd-DTPA-BMEA)
and gadopentetate dimeglumine (Magnevist®; Gd-DTPA).
Up-to-date information on the number of reported cases for
individual contrast agents as well as the regulatory status
can be obtained on the websites of regulatory agencies such
as the FDA [3].
In a previous investigation we have established a
preclinical dosing regimen simulating the prolonged
exposure to GBCAs seen in patients with severe renal
impairment [8]. In that investigation a possible association
between gadolinium exposure and the occurrence of NSF-
like lesions in the investigated rats was established [8]. The
aim of the present investigation is to further explore the
differences between various marketed Gd-containing con-
trast agents regarding their potential to trigger NSF-like




The tested Gd-containing contrast agents are all approved
and marketed products and were purchased from their
respective manufacturers. The following compounds were
tested: Omniscan (gadodiamide, Gd-DTPA-BMA, GE
Healthcare), OptiMARK (gadoversetamide, Gd-DTPA-
BMEA, Covidien), Magnevist (gadopentetate dimeglu-
mine, Gd-DTPA, Bayer Schering Pharma), MultiHance
(gadobenate dimeglumine, Gd-BOPTA, Bracco Diagnos-
tics), Gadovist (gadobutrol, Gd-BT-DO3A, Bayer Schering
Pharma) and Dotarem (gadoterate meglumine, Gd-DOTA,
Guerbet).2
Animals
Forty-two Hannover Wistar Rats [CRL:WI (GIx/BRL/
HAN)IGS BR] were obtained from Charles River (Sulz-
feld, Germany), each weighing between 190 and 240 g. Six
animals per group were selected at random and were
housed with a 12-h day and night rhythm and were given
water and standard diet (ssniff R/M-H from Sniff,
Germany) ad libitum. Animals were treated according to
the German Law on the Protection of Animals and with
permission from the state animal welfare committee.
Study design
The investigation used the methodology previously
established to simulate the high exposure to Gd-containing
contrast agents in patients with severe renal impairment [8].
The formulations were injected into a tail vein daily, five
times per week (not on weekends) at a dose of 2.5 mmol
Gd/kg body weight over a period of 4 weeks. As the
investigation control we used isotonic saline (0.9%)
solution (Table 1). The animals were sacrificed 5 days
following the last treatment. This time point was chosen on
the basis of serum elimination pharmacokinetics of the
various compounds to ensure that the administered Gd
compounds were completely eliminated from the body.
Macroscopic skin findings, histology
and immunohistochemistry
The animals were examined for macroscopic skin changes
such as reddening, fur loss, scab formation and ulceration
prior to every injection. At the end of the experiment the
backs of the animals were shaved for better visualisation of
the skin findings.
Immediately after necropsy, three skin probes were used
to take skin samples from the back of each animal. The
samples were taken from similar areas in each animal. The
probes were fixed in 4% neutral buffered formalin. After
fixation and routine dehydration, the tissue samples were
embedded in paraffin and sectioned for hematoxylin-eosin
and immunohistochemical staining. The histopathological
reading was performed by two board-certified veterinary
histopathologists (JW, FS) in a blinded fashion according
to best practice guidelines of the Society of Toxicologic
Pathology [12]. In general, structure and classification of
the histopathology evaluation followed the logical frame-
work described elsewhere [13, 14]. The severity of the
findings was graded using scores from 1 to 5 based on the
increases in cellularity (namely increases in fibroblast-like








Omniscan* 6 20 2.5 50
OptiMARK 6 20 2.5 50
Magnevist* 6 20 2.5 50
MultiHance 6 20 2.5 50
Dotarem 6 20 2.5 50
Gadovist 6 20 2.5 50
Saline 6 20 – –
*Presented already in first publication [8]
2 As it is easy to confuse the different agents due to the very similar
generic names and chemical abbreviations, as happened in the key
publication by Grobner et al. [6], we have opted for using in this
publication only the brand names as only the marketed formulations
are investigated.
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cells, dendritic-like cells and lymphocytes) (1=minimal,
2=slight, 3=moderate, 4=marked, 5=massive).
Furthermore we performed CD34 stains of the dermis
with the same methodology as described previously [8].
Cell counts
For the cell count in the skin, paraffin sections were
dewaxed, rehydrated and stained with 4′,6-diamidino-2-
phenylindole dihydrochloride (DAPI) (Sigma, St. Louis,
MO, USA). Three skin samples were taken from each
animal; two sections per sample were stained and two
regions of interest (ROIs) per section (i.e., 12 ROIs per
animal) were counted with the help of a cell-count software
programme (Cellprofiler; www.cellprofiler.org). The ROIs
were placed in the upper dermis to avoid areas with hair
follicles, glands and fat tissue.
Gadolinium, zinc and copper measurements
Measurements of the Gd, Zn and Cu concentrations in the
skin (samples taken from the back, next to the histology
probes), the liver, and the femur were made by inductive
coupled plasma atomic emission spectroscopy (ICP-AES,
IRIS Advantage, Thermo) at wavelengths of 342.247,
213.856 and 224.700 nm, respectively [15]. It should be
noted that this method cannot distinguish between chelated
or unchelated metal ions, in particular chelated or
unchelated Gd.
Statistical evaluation
Gadolinium measurements (excluding saline control ani-
mals, where no Gd was detected) were tested globally for
differences in medians between at least two groups with the
non-parametric Kruskal-Wallis test. In case of significance
at a two-sided 5% level of significance, pairwise
comparisons were performed using the non-parametric
multi-comparison Dunn’s test to ensure an experiment-
wise two-sided level of significance of 5%.
For the Cu and Zn concentrations, each treatment group
was compared with the saline control, and a one-sided 5%
level of significance (p≤0.05) was used to assess non-
inferiority to saline (Dunnett’s test). The non-inferiority
margin was chosen as the mean of the saline group minus
three times the standard deviation.
Results
Macroscopic and microscopic findings, histology,
and immunohistochemistry
Five days after the 20th injection, macroscopic changes of
the skin were observed in four out of six animals in the
Omniscan-treated group. (Table 2, Figs. 1 and 2). Those
findings included ulceration and crust formation. No mac-
roscopic changes were observed in any of the other treatment
groups or in the saline control group (Figs. 1 and 2).
On the histological level, fibrosis, including collagen
deposit, loss of the extracellular space, thickening of the
dermis and increased cellularity were observed in five out
of six animals treated with Omniscan. Furthermore, an
increase in the number of CD34-positive cells in the skin of
the animals showing fibrosis (animals treated with
Omniscan) was observed (data not shown). No histopath-
ological findings of any severity were noted for any of the
other investigated agents. Figure 2 shows a representative
image from each treatment group.
Cell counts
To quantify the increase in cellularity, we counted the
numbers of cells in the dermis, excluding the cells
Table 2 Overview of the observed macroscopic and microscopic findings in the dermis 5 days after the last injection
Macroscopic changes Microscopic changes
Increased cellularity Fibrosis sclerosis
Agent No. of animals No. of animals Mean severity score
(affected animals)
No. of animals Mean severity score
(affected animals)
Omniscan 4/6 5/6 1 5/6 1.4
OptiMARK 0/6 0/6 – 0/6 –
Magnevist 0/6 0/6 – 0/6 –
MultiHance 0/5 0/5 – 0/5 –
Dotarem 0/6 0/6 – 0/6 –
Gadovist 0/6 0/6 – 0/6 –
Saline 0/6 0/6 – 0/6 –
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associated with hair follicles, fat tissue and glands. We
observed an increase in the number of cells in all the
Omniscan-treated animals, which showed macroscopic
changes of the skin (Fig. 3). No significant differences in
cell counts were observed between the animals in the other
treatments and the control group.
Gadolinium levels in the skin
Very high Gd concentrations were observed in skin samples
from animals treated with Omniscan (1.70±0.24 μmol/g
Fig. 1 Gross lesions in the skin of animals 5 days after the last
injection of the indicated contrast media. Overview of the back of
animals. One representative animal per group is shown. For better
visibility of skin lesions, the animals were shaved (bottom right).
The number of animals showing macrocopical skin lesions and the
total number of animals is given. Please note that during the
experiment one of the Multihance treated animals died. Skin lesions
were observed only in animals treated with Omniscan (arrowhead)
"Fig. 2 Fibrosing dermopathy in rat skin. Hematoxylin stain of skin
probes taken 5 days after the last injection of the respective contrast
media. Images a–g (lefthand column) shown at 5× magnification,
while images h–n (righthand column) show 20× magnification of
the dermis. Fibrosis of the dermis was observed in the Omniscan-
treated (a, h) animals only
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skin) (Fig. 4). The Gd concentration detected in the animals
treated with Omniscan was almost 10-fold higher compared
with the Gd concentration obtained following the admin-
istration of Magnevist and more than 30-fold higher
compared to Gd concentrations detected following the
administration of Gadovist and Dotarem. A global com-
parison of median Gd levels showed that the Omniscan
treatment group had significantly higher Gd levels than all
Fig. 3 Quantification of the
increased cellularity. a Average
number of cells observed in an
individual animal treated with
indicated contrast agents. b
Nuclei (i.e. cells) are counted
in paraffin sections stained with
DAPI. c Average number of
cells observed in treatment
group. The number of cells is
given per ROI. Asterisks indi-
cate the animals with macro-




Fig. 4 Gadolinium concentra-
tions in the skin 5 days after the
last injection of the indicated
compound. Standard deviations
are indicated by the error bars.
Gd concentration after Omnis-
can administration was signifi-
cantly higher compared to all
other treatment groups (*).
MultiHance is excreted up to
50% hepatobiliarly in rats (#).
Gd concentrations after Dotarem
and Gadovist were significantly
lower than after administration
of Omniscan, OptiMARK or
Magnevist
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other treatment groups. A significantly lower Gd level was
detected after application of OptiMARK (0.43±0.09 μmol/
g skin), which contains twice the amount of excess ligand as
compared to Omniscan. TheMagnevist (0.18±0.08 μmol/g
skin) and MultiHance (0.08±0.01 μmol/g skin) treatment
groups also had significantly lower Gd levels than the
Omniscan group. Gadolinium levels in the macrocyclic
agents Gadovist (0.05±0.01 μmol/g skin) and Dotarem
(0.05±0.01 μmol/g skin) treatment groups were the lowest
of all investigated agents (Fig. 4).
Gadolinium levels in the liver and femur
In the liver and femur, the highest levels of Gd were again
observed following treatment with Omniscan, with signif-
icant differences observed between Omniscan and all other
treatment groups based on analyses of the median Gd
levels (Fig. 5).
Zinc and copper levels in the skin, liver and femur
No significant loss of zinc and copper were observed for
any of the treatment or control groups (Fig. 6).
Discussion
The possible association between the use of Gd-containing
contrast agents in magnetic resonance imaging and the
development of NSF in patients with severe renal
impairment has been widely reported in the medical
literature in recent months [6, 11, 16]. We initiated a range
of preclinical in vivo studies to investigate this further. In an
earlier investigation, a strong correlation was found between
the gadolinium concentration in the skin and the develop-
ment of NSF-like skin lesions in our preclinical setting [8].
The present investigation was performed to compare
different marketed extracellular GBCAs in addition to the
Fig. 5 Gadolinium concentra-
tions in the femur (a) and liver
(b) 5 days after the last injection
of the indicated compound.
Standard deviations are indi-
cated by the error bars. Gd
concentration after Omniscan
administration was significantly
higher compared to all other
treatment groups (*). Multi-
Hance is excreted up to 50%
hepatobiliarly in rats (#). In the
femur Gd concentrations after
Dotarem and Gadovist were




Magnevist and Omniscan groups already reported in the first
publication [8].
After investigation of different key GBCAs in this
setting, NSF-like skin lesions were only found in animals
treated with Omniscan. In the skin of patients with NSF the
lesions are accompanied by an increase in fibroblast-like
cells, dermal macrophages and fibrocytes positive for CD34
and procollagen [17–19]. Additionally, there may be a
considerable increase in collagen bundles and, in some cases,
deposits of mucin in the skin [20, 21]. Microscopic changes
similar to those described in human NSF patients were
observed in the rats showingmacroscopic skin changes (only
animals treated with Omniscan). The development of
fibrosis, including increased cellularity and increased cell
swelling causing a loss of interstitial space was observed in
five out of six animals treated with Omniscan. Furthermore,
these changes were accompanied by an increased dermal cell
count. We also found an increase in the number of CD34-
positive cells in the dermis of those animals showing fibrosis
[8]. It is important to note, however, that we observed
differences in the histopathology between that reported in
human NSF patients and the rats used in our experimental
setting. For example, in the rats, we did not see the deep
infiltration of the sub-cutis found in humanNSF patients. It is
possible that this difference is due to the different histology of
the skin in rats [8].
The occurrence of these skin lesions seems to be
strongly correlated with high Gd concentrations, particu-
larly in the skin, but also in the liver and the femur,
confirming the previous finding [8], which suggests that
there may be a relationship between the release of Gd and
the occurrence of the NSF-like lesions.
Stability/inertness characteristics measured in vitro
describe the likelihood of Gd release from the Gd-chelate
in vitro, which may be a predictor for release of Gd ions in
vivo. In our setting we were able to test whether in vitro
stability data correlate with Gd concentrations in the skin of
the investigated animals.
Regarding their in vitro stability, Gd-containing contrast
agents fall into two distinct classes: the linear, open-chain
agents and the macrocyclic agents [22].
Fig. 6 Zinc (a) and copper (b)
concentrations in the skin
(purple), liver (yellow) and
femur (green) 5 days after the




Linear complexes differ significantly in their stability,
which may be adequately described by the thermody-
namic stability constant (log Ktherm, valid at pH=14)
and the conditional stability constant log Kcond (calcu-
lated for pH=7.4). The addition of an ionic charge
enhances the stability of the complex, with the ionic
linear complexes (e.g. Magnevist and MultiHance)
being about 3.5 orders of magnitude (or approximately
a factor of 3,000) more stable than the non-ionic linear
complexes (Omniscan and OptiMARK) (Table 3,
Fig. 7a). To compensate for their lower stability, the
non-ionic linear compounds, Omniscan and OptiMark,
are formulated with 5 mol% and 10 mol% excess
ligand, respectively [23].
In vitro data demonstrate that macrocyclic Gd chelates
are kinetically inert to Gd dissociation compared to linear
Gd chelates [24–26] since a substantial activation energy
barrier has to be overcome for both the complexation and
the de-complexation of marketed macrocyclic agents
(Fig. 7b). The reason for this phenomenon is the fact that
the macrocyclic ring system is very rigid and additional
energy is needed to set the complexed gadolinium free
Table 3 Relevant stability parameters [25] of the investigated linear chelates
Contrast agent Charge Thermodynamic stability
(log Ktherm, pH 14)
Conditional stability
(log Kcond, pH 7.4)
Excess free ligand
in formulation (mg/ml)
Omniscan Non-ionic 16.9 14.9 12
OptiMARK Non-ionic 16.6 15.0 28.4
Magnevist Ionic 22.5 18.4 0.4
MultiHance Ionic 22.6 18.4 0.4 [30]a
aRecent information suggests that in the presently marketed formulation of MultiHance no excess ligand is contained
Fig. 7 Differences in stability/
inertness of gadolinium-
containing contrast agents. The
differences between non-ionic
and ionic linear agents (a) and
between linear and macrocyclic
agents (b) are depicted
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from the sterically hindered (bulky) macrocycle. Therefore
the propensity of macrocylic GBCAs to release gadolinium
is best described by the kinetic constant (kobs, measured at
pH=1.0 and derived from the dissociation half-life) and not
by the thermodynamic stability constants log Ktherm and
log Kcond (Table 4) [25].
In our experimental setting, Omniscan exposure resulted
in the highest Gd concentrations of all tested agents,
especially in the skin, followed by OptiMARK. As the
stability constants of the two agents are similar, this
suggests that the difference in Gd concentration is caused
by the different amount of excess ligand. We were able to
confirm this role of the excess ligand in a separate series of
experiments more thoroughly [27].
Significantly smaller Gd concentrations were measured
in the animals treated with the ionic linear agents
Magnevist and MultiHance compared to both non-ionic
linear agents. As described above, ionic linear agents are
characterized by a higher in vitro stability as compared to
non-ionic linear agents. The difference in the Gd concen-
tration observed between MultiHance- and Magnevist-
treated animals can, however, not be easily explained by
differences in in vitro stabilities, as those were very similar
(see Table 3). The observation can most likely be explained
by the different exposure of the animals to the contrast
agents. MultiHance is excreted up to 50% via the
hepatobiliary system in rats [28] causing faster excretion
and thereby a lower AUC. This difference compared to the
other GBCAs is not seen in humans, where the hepatobil-
iary excretion of MultiHance accounts only for 0.6–4%
[29]. Therefore, the observations regarding the Gd con-
centration after treatment with MultiHance in the rat model
may not be an accurate predictor of the clinical situation.
The lowest Gd concentrations, significantly lower than
the Gd concentrations of all linear agents with similar
pharmacokinetic clearance, were measured in the animals
treated with the macrocyclic Gd chelates Gadovist and
Dotarem. Although the kinetic half-lifes measured in vitro
at pH 1.0 for Gadovist and Dotarem were not identical (see
Table 4), the present investigation found virtually identical,
low levels of Gd in the skin. This finding suggests that
there are no relevant stability differences of the macro-
cyclic compounds in vivo as already postulated based on
the very long extrapolated dissociation half-life in vitro at
pH 7.4 [25].
Given their high stability, it may be expected that no Gd
would be detectable in animals treated with the two tested
macrocyclic agents, Gadovist and Dotarem. However, in
our experimental setting, Gd was detected with both
agents, albeit at significantly lower amounts. The residual
Gd could be related to the specifics of the ICP-AES
method, which can not distinguish between chelated and
unchelated gadolinium. It is possible that some or all of the
residual Gd measured in the tissue specimens taken 5 days
after the last injection arises from chelated Gd, which will
not be retained in the skin but eliminated over time. Of
course, the same caveat applies to the Gd concentrations
measured after the applications of all other agents in the
study. However, we did demonstrate in our first experiment
that unchelated Gd is present in precipitates in the skin of
animals treated with Omniscan [8]. Studies to measure the
time course of Gd retention in the skin are currently being
conducted, but results are not yet available.
To summarize the data obtained in this investigation
(given the limitations of the experimental setting), non-
ionic linear Omniscan seems clearly to be the agent with
the highest risk of releasing Gd ions in vivo (the situation is
slightly improved with the addition of more excess ligand,
as in OptiMARK), while the risk is significantly reduced
with ionic linear agents, such as Magnevist and Multi-
Hance, and even further reduced with macrocyclic agents,
such as Gadovist and Dotarem.
Although in our preclinical setting NSF-like skin lesions
were noted to occur only in the Omniscan treatment group,
cases of NSF reported to date in humans have been
associated with the use, not only of Omniscan, but also of
other GBCAs as well (for latest information refer to the
websites of health authorities such as the FDA). Further-
more, since residual Gd concentrations were found in this
experiment for the non-Omniscan animals, the risk for NSF
can not be excluded for the other agents.
In conclusion, our preclinical experiments suggest that
the different in vitro stabilities of the Gd-containing
contrast agents result in different propensities to release
Gd, particularly in the skin. The findings of this
investigation support the conclusion that the complex
stability of GBCAs is correlated with the likelihood of
releasing Gd ions in vivo. It remains to be seen whether
these findings correlate with a different risk of NSF.
Table 4 Relevant stability parameters [25] of the investigated macrocyclic chelates
Contrast agent Charge Dissociation rate kobs
(s–1) (pH 1.0)
Dissociation half-life
(T1/2 at pH 1.0, calculated from kobs)
Dissociation half-life
(T1/2, extrapolated to pH 7.4)
Dotarem Ionic 2.1×10–5 9 h > 1,000 years
3.2×10–6 60 h
Gadovist Non-ionic 8.0×10–6 24 h > 1,000 years
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